Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285665211> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4285665211 endingPage "340" @default.
- W4285665211 startingPage "335" @default.
- W4285665211 abstract "The current treatment strategy for rheumatoid arthritis has been formulated within the framework of the European League Against Rheumatism (EULAR) concept “Treatment to achieve the goal”. Methotrexate prescribed as soon as possible after verifying rheumatoid arthritis is recognized as a first-line drug that allows to achieve disease remission and prevent destructive changes in the joints. Long-term clinical experience of using methotrexate allowed to conclude that almost 30% patients with rheumatoid arthritis turn out to be resistant to such treatment, enforcing to change the basal anti-inflammatory therapy, shift to using targeted or genetically engineered biological drugs, so that timeframe to prevent disease progression can be irreversibly lost. In the last decade, genetic testing for drug therapy effectiveness has been gaining momentum based on individual features in functioning of enzyme systems which regulate various stages of drug biotransformation. To date, a personalized approach to treatment of rheumatoid arthritis may be implemented after examining more than a dozen of single nucleotide polymorphisms (SNPs) within the folate cycle genes responsible for metabolizing methotrexate as well as its mechanism of action. In our work, we attempted to test a relationship between therapeutic response (efficacy and resistance) to methotrexate and -401CT (rs 3758149) SNP in the GGH (gamma-glutamyl hydrolase) gene, which coordinates the processes of extracellular methotrexate transport. A groups patients consisted of 85 basic anti-inflammatory therapy-naïve patients diagnosed with rheumatoid arthritis, who were initially treated with methotrexate at a dose of 10 to 17.5 mg per week, with subsequently assessed therapeutic efficacy 6 months after the treatment onset based on dynamics in DAS28 index that allowed to identify groups of “responders” and “non-responders”. Next, all patients from select groups underwent molecular genetic typing for GGH-401CT SNP by using real-time polymerase chain reaction. Our study allowed to find that prevalence of the TT homozygous genotype (OR = 5.09; 95% CI 1.11- 23.3; p = 0.037) dominated in “methotrexate non-responders”, whereas “methotrexate responders” tended to have higher C allele frequency (OR = 0.54; 95% CI 0.27-1.01; p = 0.087), which allowed to identify them by genetic predictors of methotrexate therapeutic response in rheumatoid arthritis." @default.
- W4285665211 created "2022-07-17" @default.
- W4285665211 creator A5039468395 @default.
- W4285665211 creator A5043115837 @default.
- W4285665211 creator A5048970583 @default.
- W4285665211 creator A5088454937 @default.
- W4285665211 creator A5092330823 @default.
- W4285665211 date "2020-07-15" @default.
- W4285665211 modified "2023-10-17" @default.
- W4285665211 title "Gamma-glutamyl hydrolase gene polymorphisms – another way to predict methotrexate efficacy in rheumatoid arthritis" @default.
- W4285665211 cites W2010650782 @default.
- W4285665211 cites W2012495442 @default.
- W4285665211 cites W2049899981 @default.
- W4285665211 cites W2062630004 @default.
- W4285665211 cites W2120393706 @default.
- W4285665211 cites W2128952811 @default.
- W4285665211 cites W2525856192 @default.
- W4285665211 cites W2537850200 @default.
- W4285665211 cites W2883142851 @default.
- W4285665211 cites W2979466567 @default.
- W4285665211 doi "https://doi.org/10.46235/1028-7221-333-ghg" @default.
- W4285665211 hasPublicationYear "2020" @default.
- W4285665211 type Work @default.
- W4285665211 citedByCount "0" @default.
- W4285665211 crossrefType "journal-article" @default.
- W4285665211 hasAuthorship W4285665211A5039468395 @default.
- W4285665211 hasAuthorship W4285665211A5043115837 @default.
- W4285665211 hasAuthorship W4285665211A5048970583 @default.
- W4285665211 hasAuthorship W4285665211A5088454937 @default.
- W4285665211 hasAuthorship W4285665211A5092330823 @default.
- W4285665211 hasBestOaLocation W42856652111 @default.
- W4285665211 hasConcept C126322002 @default.
- W4285665211 hasConcept C203014093 @default.
- W4285665211 hasConcept C2777077863 @default.
- W4285665211 hasConcept C2777489490 @default.
- W4285665211 hasConcept C2777575956 @default.
- W4285665211 hasConcept C2780035454 @default.
- W4285665211 hasConcept C2781059491 @default.
- W4285665211 hasConcept C71924100 @default.
- W4285665211 hasConcept C98274493 @default.
- W4285665211 hasConceptScore W4285665211C126322002 @default.
- W4285665211 hasConceptScore W4285665211C203014093 @default.
- W4285665211 hasConceptScore W4285665211C2777077863 @default.
- W4285665211 hasConceptScore W4285665211C2777489490 @default.
- W4285665211 hasConceptScore W4285665211C2777575956 @default.
- W4285665211 hasConceptScore W4285665211C2780035454 @default.
- W4285665211 hasConceptScore W4285665211C2781059491 @default.
- W4285665211 hasConceptScore W4285665211C71924100 @default.
- W4285665211 hasConceptScore W4285665211C98274493 @default.
- W4285665211 hasIssue "3" @default.
- W4285665211 hasLocation W42856652111 @default.
- W4285665211 hasOpenAccess W4285665211 @default.
- W4285665211 hasPrimaryLocation W42856652111 @default.
- W4285665211 hasRelatedWork W1977601919 @default.
- W4285665211 hasRelatedWork W1996155052 @default.
- W4285665211 hasRelatedWork W2001317021 @default.
- W4285665211 hasRelatedWork W2092353997 @default.
- W4285665211 hasRelatedWork W2602481810 @default.
- W4285665211 hasRelatedWork W2616933475 @default.
- W4285665211 hasRelatedWork W2911506796 @default.
- W4285665211 hasRelatedWork W2945580545 @default.
- W4285665211 hasRelatedWork W3163812575 @default.
- W4285665211 hasRelatedWork W4256594459 @default.
- W4285665211 hasVolume "23" @default.
- W4285665211 isParatext "false" @default.
- W4285665211 isRetracted "false" @default.
- W4285665211 workType "article" @default.